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Breast cancer is the most common cancer among American and Japanese women,[1](#cas13221-bib-0001){ref-type="ref"} with about one in eight (12%) women in the United States and one in 16 (6%) in Japan developing invasive breast cancer during their lifetime. In Japan, the predicted incidence of breast cancer is 90 000 (the most common cancer in women), with 14 000 breast cancer deaths (the fifth leading cause of death in women) in 2016.[2](#cas13221-bib-0002){ref-type="ref"}

Taxane‐containing regimens were shown to improve overall survival (OS) in women with metastatic breast cancer (MBC) in a large systematic review,[3](#cas13221-bib-0003){ref-type="ref"} while concurrent combined use of anthracyclines and taxanes failed to prolong OS compared with single and sequential use of each drug.[4](#cas13221-bib-0004){ref-type="ref"}, [5](#cas13221-bib-0005){ref-type="ref"}, [6](#cas13221-bib-0006){ref-type="ref"} The single use of taxanes, such as paclitaxel and docetaxel, has thus become one of the first‐line regimens for MBC.[7](#cas13221-bib-0007){ref-type="ref"}, [8](#cas13221-bib-0008){ref-type="ref"}

Weekly (qw) administration of paclitaxel in patients with MBC was more effective than administration every 3‐weeks (q3w) in terms of overall response rate (ORR), time to progression and OS (CALGB 9840).[9](#cas13221-bib-0009){ref-type="ref"} In an adjuvant setting, paclitaxel qw (hazard ratio \[HR\]: 1.27, *P *=* *0.006) and docetaxel q3w (HR: 1.23, *P *=* *0.02) were superior to paclitaxel q3w in terms of disease‐free survival, and OS was higher with paclitaxel qw (HR: 1.32, *P *=* *0.01) compared with paclitaxel q3w.[10](#cas13221-bib-0010){ref-type="ref"} Based on this evidence, patients with MBC patients are often treated with paclitaxel qw or docetaxel q3w in clinical practice.

However, solvent‐based paclitaxel (*sb*‐paclitaxel) and docetaxel formulations have several limitations; both require solvents (Cremophor EL or polysorbate 80) to increase their solubility, and these solvents are associated with the development of hypersensitivity and decreased efficiency of drug delivery to the tumor.[11](#cas13221-bib-0011){ref-type="ref"}, [12](#cas13221-bib-0012){ref-type="ref"}, [13](#cas13221-bib-0013){ref-type="ref"} In contrast, nanoparticle albumin‐bound paclitaxel (*nab*‐paclitaxel) is a solvent‐free albumin‐bound form of paclitaxel, which enables it to be administered more quickly, without the need for steroids and anti‐histamine premedication to reduce solvent‐related hypersensitivity reactions. Compared with *sb*‐paclitaxel, *nab*‐paclitaxel demonstrated enhanced transport across endothelial cell monolayers and increased tumor delivery of paclitaxel.[14](#cas13221-bib-0014){ref-type="ref"}, [15](#cas13221-bib-0015){ref-type="ref"}

In a phase III trial, *nab*‐paclitaxel q3w at a dose of 260 mg/m^2^ demonstrated a significantly higher ORR compared with *sb*‐paclitaxel in patients with MBC.[16](#cas13221-bib-0016){ref-type="ref"} Based on the results for *sb*‐paclitaxel, *nab*‐paclitaxel qw is also expected to have greater efficacy than *nab*‐paclitaxel q3w. Additionally, *nab*‐paclitaxel qw has been reported to allow a facilitate relative dose intensity, with improved antitumor activity compared with q3w.[17](#cas13221-bib-0017){ref-type="ref"}, [18](#cas13221-bib-0018){ref-type="ref"} Indeed, a phase II study demonstrated significantly longer progression‐free survival (PFS) with *nab*‐paclitaxel 150 mg/m^2^ qw as first‐line therapy compared with docetaxel 100 mg/m^2^ q3w, with a favorable safety profile in patients with MBC, most of whom were Caucasian.[19](#cas13221-bib-0019){ref-type="ref"} *Nab*‐paclitaxel (150 mg/m^2^) also showed favorable tolerability in a phase I study involving Japanese patients with MBC.[20](#cas13221-bib-0020){ref-type="ref"}

Based on these results, we investigated further qw dosing schedules of *nab*‐paclitaxel in Japanese patients with MBC. Docetaxel 75 mg/m^2^ was determined to be a tolerable dose based on previous studies in Japanese breast cancer patients.[21](#cas13221-bib-0021){ref-type="ref"} We therefore aimed to compare the efficacy and safety profiles of *nab*‐paclitaxel 150 mg/m^2^ qw and docetaxel 75 mg/m^2^ in Japanese patients with MBC.

Materials and Methods {#cas13221-sec-0002}
=====================

Study design {#cas13221-sec-0003}
------------

This multicenter, randomized, controlled, open‐label phase II study was conducted at 21 sites in Japan. The primary endpoint was PFS by independent radiologist assessment, which was defined as the time from enrollment until tumor progression or death from any cause, with censoring of patients who were lost to follow‐up. The secondary endpoints were ORR (proportion of patients who achieved a complete response \[CR\] or partial response \[PR\]), time to treatment failure (TTF; time from the date of enrollment to earliest date of last study drug administration, objective progressive disease \[PD\] or death) and OS. The disease control rate (proportion of patients who achieved CR, PR or stable disease) was also assessed. The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines, and was approved by the ethical committee or review board of each institution. All patients provided written consent before their enrollment.

Patients {#cas13221-sec-0004}
--------

The main inclusion criteria were as follows: female sex; histologically or cytologically confirmed breast cancer; clinically confirmed MBC, with no history of chemotherapy after confirmation of metastasis; MBC without human epidermal growth factor receptor 2 overexpression determined by immunohistochemical staining or FISH (patients with immunohistochemical 3+ or 2+ and FISH‐positive results were excluded from the study); at least one measurable lesion defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 within 28 days prior to enrollment; Eastern Cooperative Oncology Group performance status (PS) of 0--1; retained organ functions; and no prior chemotherapy except for adjuvant/neoadjuvant chemotherapy. The main exclusion criteria were as follows: recurrence within 12 months after the last treatment with taxane therapy before/after surgery, or progression during taxane therapy prior to surgery; symptomatic or treatment‐requiring brain metastasis; pleural fluid; ascites; grade ≥2 pre‐existing peripheral neuropathy; or pericardial fluid requiring drainage.

Treatment {#cas13221-sec-0005}
---------

Patients were randomly assigned (1:1) via a centralized randomization system to receive either *nab*‐paclitaxel or docetaxel using a minimization allocation method. The randomization procedure was generated by EPS Corporation (Tokyo, Japan), independent of the sponsor. The randomization was stratified by prior received taxanes as adjuvant therapy (yes or no) and Eastern Cooperative Oncology Group PS (0 or 1). *Nab*‐paclitaxel at an initial dose of 150 mg/m^2^ was administered intravenously over 30 min, qw for 3 of 4 weeks. Dose reductions were permitted to manage toxicities such as neutropenia, thrombocytopenia, or non‐hematologic toxicities (Table [S1](#cas13221-sup-0001){ref-type="supplementary-material"}). Patients requiring further dose reduction than 80 mg/m^2^ (level 3) were withdrawn from the study (Tables [S1](#cas13221-sup-0001){ref-type="supplementary-material"}, [S2](#cas13221-sup-0001){ref-type="supplementary-material"}). Dose‐interruption criteria on Days 8 and 15 are shown in Table [S3](#cas13221-sup-0001){ref-type="supplementary-material"}. A new treatment cycle was postponed for a maximum of 21 days if one or more criteria for starting the next cycle were not met (Table [S4](#cas13221-sup-0001){ref-type="supplementary-material"}). The postponed cycle or omitted dosing was resumed after confirming that the criteria to start the next cycle were met.

Docetaxel at a dose of 75 mg/m^2^ was injected intravenously over 1 h, q3w. Dose reductions to 60 and 50 mg/m^2^ were permitted, according to the same criteria described for *nab*‐paclitaxel above. Discontinuation, dose omission, and cycle resumption were determined according to the same criteria as for *nab*‐paclitaxel.

The cycles for both study drugs were repeated until disease progression, development of unacceptable toxicity, or withdrawal of consent.

Assessments {#cas13221-sec-0006}
-----------

Tumor assessment was done at screening and every 6 weeks from randomization. Additional assessments were carried out if disease progression was suspected. Tumor responses were evaluated according to the RECIST version 1.0.[22](#cas13221-bib-0022){ref-type="ref"} Tumor assessments were carried out by the independent radiologist assessment (ICON Medical Imaging, PA, USA) and by the investigators.

Adverse events were recorded and graded according to the Common Terminology Criteria for Adverse Events version 3.0.

Statistical analysis {#cas13221-sec-0007}
--------------------

Efficacy data were analyzed for the full analysis set, defined as eligible patients who received the study drug at least once. Pre‐specified subgroup analyses of OS and PFS were performed to assess the effects of prior use of adjuvant taxanes and of triple‐negative breast cancer (TNBC). The primary endpoint was analyzed at a 5% significance level using the log‐rank test and Cox\'s proportional hazards model. Survival was analyzed using medians with 90% or 95% confidence intervals (CI), respectively, using Kaplan--Meier estimates. ORR was compared between the two treatment arms using Fisher\'s exact test. TTF and OS were analyzed as for PFS with 95% CI.

We assumed the median PFS for *nab*‐paclitaxel 150 mg/m^2^ qw was 11.8 months and that for docetaxel 75 mg/m^2^ was 7.5 months, based on the results of a previous phase II study by Gradishar *et al*.[19](#cas13221-bib-0019){ref-type="ref"} We calculated that 152 patients would be needed to demonstrate the superiority of *nab*‐paclitaxel 150 mg/m^2^ qw compared with docetaxel 75 mg/m^2^ q3w at a one‐sided 0.05 significance level and power of 80%. Assuming that 5% of patients might be excluded from the full analysis set, we estimated that we required to enroll 160 patients in the present study. During the recruitment process, we revised this estimate to 192 patients to account for the fact that the number of PD events judged by an independent radiologist assessment tends to be lower than that judged by the investigator, based on a previous study of 762 patients, of whom 635 were judged to have PD according to the investigators' assessment, compared with only 521 according to the independent radiologist assessment.[23](#cas13221-bib-0023){ref-type="ref"} The number of needed events (121 events) was not modified.

Results {#cas13221-sec-0008}
=======

Patients {#cas13221-sec-0009}
--------

From November 2009 to December 2012, 200 patients were enrolled in this study, of whom 197 were assessed as eligible. Figure [1](#cas13221-fig-0001){ref-type="fig"} shows the CONSORT flow diagram of the study. A total of 200 patients were allocated to the two treatment arms, with 100 patients in each. All 200 patients received at least one treatment and served as the safety analysis population. Three patients were excluded from the full analysis set because of protocol deviations, including two in the *nab*‐paclitaxel and one in the docetaxel arm. The major reasons for treatment discontinuation were disease progression (57.1% *nab*‐paclitaxel, 45.5% docetaxel) and adverse events (26.5% *nab*‐paclitaxel, 27.3% docetaxel) (Fig. [1](#cas13221-fig-0001){ref-type="fig"}). The cut‐off date for the primary endpoint was 31 January 2013, and the median follow‐up time was 23.0 months.

![CONSORT flow diagram.](CAS-108-987-g001){#cas13221-fig-0001}

Patient characteristics (full analysis set) were balanced between the *nab*‐paclitaxel and docetaxel arms, respectively (Table [1](#cas13221-tbl-0001){ref-type="table-wrap"}), including median age (60 *vs* 58 years), age \<65 years (76.5% *vs* 81.8%), ratio of TNBC (21.4% *vs* 15.2%), and prior receipt of taxanes as adjuvant chemotherapy (27.6% *vs* 30.3%).

###### 

Patient demographics and characteristics

                                                            *Nab*‐paclitaxel (*n *=* *98)   Docetaxel (*n *=* *99)   *P*‐value[†](#cas13221-note-0003){ref-type="fn"}             
  --------------------------------------------------------- ------------------------------- ------------------------ -------------------------------------------------- --------- ----------
  Sex                                                                                                                                                                             
  Female                                                    98                              (100.0)                  99                                                 (100.0)   
  Age (years)                                                                                                                                                                     
  Median                                                    60.0                                                     58.0                                                         
  Range \[min, max\]                                        \[25, 74\]                                               \[33, 74\]                                                   
  ECOG performance status                                                                                                                                                         
  0                                                         87                              (88.8)                   86                                                 (86.9)    F: 0.828
  1                                                         11                              (11.2)                   13                                                 (13.1)    
  Triple negative                                                                                                                                                                 
  Yes                                                       21                              (21.4)                   15                                                 (15.2)    F: 0.274
  Estrogen receptor                                                                                                                                                               
  Negative                                                  23                              (23.5)                   16                                                 (16.2)    C: 0.198
  Positive                                                  75                              (76.5)                   83                                                 (83.8)    
  Progesterone receptor                                                                                                                                                           
  Negative                                                  41                              (41.8)                   35                                                 (35.4)    C: 0.413
  Positive                                                  57                              (58.2)                   63                                                 (63.6)    
  Unknown                                                   0                               (0.0)                    1                                                  (1.0)     
  Organ metastases[‡](#cas13221-note-0003){ref-type="fn"}                                                                                                                         
  Lung                                                      49                              (50.0)                   42                                                 (42.4)    
  Bone                                                      44                              (44.9)                   53                                                 (53.5)    
  Lymph node                                                43                              (43.9)                   39                                                 (39.4)    
  Liver                                                     37                              (37.8)                   46                                                 (46.5)    
  Surgical history                                                                                                                                                                
  No                                                        29                              (29.6)                   34                                                 (34.3)    F: 0.542
  Yes                                                       69                              (70.4)                   65                                                 (65.7)    
  Prior adjuvant therapy with taxanes                                                                                                                                             
  *Sb*‐paclitaxel                                           13                              (13.3)                   20                                                 (20.2)    F: 0.252
  Docetaxel                                                 14                              (14.3)                   10                                                 (10.1)    F: 0.392

Analysis set: full analysis set. †F, Fisher\'s exact test; C, χ^2^ test. ^‡^Multiple answers allowed. ECOG, Eastern Cooperative Oncology Group; sb, solvent‐based.

John Wiley & Sons, Ltd

The median relative dose intensities for *nab*‐paclitaxel and docetaxel were 70.2% and 83.5%, respectively. The rates of second‐line therapy use were similar in both arms (94.9% *nab*‐paclitaxel *vs* 90.9% docetaxel).

Efficacy {#cas13221-sec-0010}
--------

The median PFS for *nab*‐paclitaxel and docetaxel by the independent radiologist assessment was 9.8 months (90% CI: 8.5--11.2) and 11.2 months (90% CI: 8.4--13.8) (HR: 1.25, *P *=* *0.363), respectively (Fig. [2](#cas13221-fig-0002){ref-type="fig"}a). The median PFS by the investigator was 11.2 months (90% CI: 9.7--12.7) and 10.6 months (90% CI: 8.5--11.3) (HR: 0.81, *P *=* *0.233), respectively (Fig. [2](#cas13221-fig-0002){ref-type="fig"}b). In the subgroup of patients who did not receive taxanes as adjuvant chemotherapy, the median PFS by the independent radiologist assessment was 10.9 months for *nab*‐paclitaxel (90% CI: 8.5--12.5) and 9.9 months (90% CI: 7.8--12.6) for docetaxel (HR: 1.05, *P *=* *0.824). There was no significant difference in PFS between patients who had and had not received taxanes as adjuvant chemotherapy (Table [2](#cas13221-tbl-0002){ref-type="table-wrap"}). The median PFS in the subgroup of patients with TNBC, by the independent radiologist was 6.8 months for *nab*‐paclitaxel (95% CI: 5.3--6.9) and 7.0 months for docetaxel (95% CI: 2.9--9.6) (HR: 1.20, *P *=* *0.624).

![Kaplan--Meier plots of progression‐free survival by the independent radiologist assessment (a) and by investigators (b) Kaplan--Meier plots of overall survival (c). CI, confidence interval.](CAS-108-987-g002){#cas13221-fig-0002}

###### 

Stratified PFS assessed by independent radiologist and investigator

                                         Treatment          Patients           PFS, months   Hazard ratio[†](#cas13221-note-0004){ref-type="fn"}   *P‐*value                             
  -------------------------------------- ------------------ ------------------ ------------- ----------------------------------------------------- ----------- ------------ ------------ -------
  Evaluated by independent radiologist                                                                                                                                                   
  Prior taxane therapy                   No                 *Nab*‐paclitaxel   71            10.9                                                  8.5, 12.5   1.05         0.72, 1.53   0.824
  Docetaxel                              71                 9.9                7.8, 12.6                                                                                                 
  Yes                                    *Nab*‐paclitaxel   27                 8.4           6.9, 12.6                                             1.73        0.94, 3.17   0.133        
  Docetaxel                              28                 15.3               11.2, 18.1                                                                                                
  Evaluated by investigator                                                                                                                                                              
  Prior taxane therapy                   No                 *Nab*‐paclitaxel   71            11.3                                                  9.4, 14.2   0.73         0.51, 1.06   0.166
  Docetaxel                              71                 9.8                7.8, 11.1                                                                                                 
  Yes                                    *Nab*‐paclitaxel   27                 9.8           8.4, 16.5                                             0.99        0.56, 1.75   0.983        
  Docetaxel                              28                 12.5               9.3, 15.4                                                                                                 

Analysis set: full analysis set. †Cox\'s proportional hazards model was used. CI, confidence interval; HR, hazard ratio; *n*, number of patients; PFS, progression‐free survival.

John Wiley & Sons, Ltd

The results for tumor response, ORR, and disease control rate are summarized in Table [3](#cas13221-tbl-0003){ref-type="table-wrap"}. There was no significant difference in ORR in the *nab*‐paclitaxel arm assessed by either the independent radiologists or investigators. The ORRs in TNBC patients were 52.4% and 46.7% in the *nab*‐paclitaxel and docetaxel arms, respectively (*P *=* *1.000).

###### 

Best overall response

                                        Independent radiologist assessment   Investigator assessment                                                                       
  ------------------------------------- ------------------------------------ ------------------------- ---- -------------- ------- ---- -------------- ---- -------------- -------
  CR                                    1                                    (1.0)                     1    (1.0)                  0    (0.0)          0    (0.0)          
  PR                                    54                                   (55.1)                    51   (51.5)                 60   (61.2)         54   (54.5)         
  SD                                    36                                   (36.7)                    34   (34.3)                 35   (35.7)         34   (34.3)         
  PD                                    5                                    (5.1)                     7    (7.1)                  1    (1.0)          6    (6.1)          
  NE                                    2                                    (2.0)                     6    (6.1)                  2    (2.0)          5    (5.1)          
  Overall response rate (CR + PR)       55                                   (56.1)                    52   (52.5)         0.669   60   (61.2)         54   (54.5)         0.388
  95% CI (%)                                                                 (45.7, 66.1)                   (42.2, 62.7)                (50.8, 70.9)        (44.2, 64.6)   
  Disease‐control rate (CR + PR + SD)   91                                   (92.9)                    86   (86.9)         0.238   95   (96.9)         88   (88.9)         0.049
  95% CI (%)                                                                 (85.8, 97.1)                   (78.6, 92.8)                (91.3, 99.4)        (81.0, 94.3)   

Analysis set: full analysis set. †Fisher\'s exact test. CI, confidence interval; CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.

John Wiley & Sons, Ltd

The median TTF in the *nab*‐paclitaxel and docetaxel arms was 7.0 months (95% CI: 5.6--8.5) and 5.7 months (4.6--7.2) (HR: 0.89, *P *=* *0.414), respectively, as assessed by an independent radiologist assessment; and 8.1 months (95% CI: 6.4--9.2) and 5.7 months (95% CI: 5.2--8.1) (HR: 0.78, *P *=* *0.117), as assessed by the investigators. The median OS for *nab*‐paclitaxel and docetaxel was 42.4 months (95% CI: 32.4--not reached) and 34.0 months (95% CI: 27.6--40.0) (HR: 0.78, *P *=* *0.190), respectively (Fig. [2](#cas13221-fig-0002){ref-type="fig"}c), and the median OS in TNBC patients was 27.1 months (95% CI: 18.1--not reached) and 19.3 months (95% CI: 14.1--26.0) (HR: 0.56, *P *=* *0.121).

Safety {#cas13221-sec-0011}
------

All patients experienced some adverse events throughout the course of the study. The commonly reported adverse events (≥30% of patients) are summarized in Table [4](#cas13221-tbl-0004){ref-type="table-wrap"}. The most frequent adverse events in the *nab*‐paclitaxel arm were neutropenia (97.0%), leukocytopenia (96.0%), alopecia (95.0%), peripheral sensory neuropathy (88.0%), rash (61.0%) and nail disorder (57.0%), and those in the docetaxel arm were neutropenia (99.0%), leukocytopenia (99.0%), alopecia (91.0%), peripheral sensory neuropathy (69.0%), taste disturbance (67.0%), and nail disorder (57.0%). Anemia, peripheral sensory neuropathy, and rash occurred in at least 10% more patients in the *nab*‐paclitaxel arm compared with the docetaxel arm, while edema, loss of appetite, and taste disturbance occurred in at least 10% more patients in the docetaxel arm.

###### 

Adverse events occurring in ≥30% of patients in any treatment group

                                 *Nab*‐paclitaxel (*n *=* *100)   Docetaxel (*n *=* *100)                                      
  ------------------------------ -------------------------------- ------------------------- ---- -------- ----- --------- ---- --------
  Any adverse events             100                              (100.0)                   88   (88.0)   100   (100.0)   99   (99.0)
  Hematologic toxicity                                                                                                         
  Neutropenia                    97                               (97.0)                    78   (78.0)   99    (99.0)    98   (98.0)
  Leukopenia                     96                               (96.0)                    58   (58.0)   99    (99.0)    90   (90.0)
  Non‐hematotologic toxicity                                                                                                   
  Alopecia                       95                               (95.0)                    0             91    (91.0)    0    
  Peripheral sensory neuropthy   88                               (88.0)                    22   (22.0)   69    (69.0)    5    (5.0)
  Rash                           61                               (61.0)                    1    (1.0)    50    (50.0)    0    
  Nail disorder                  57                               (57.0)                    0             57    (57.0)    0    
  Anemia                         51                               (51.0)                    5    (5.0)    36    (36.0)    1    (1.0)
  Arthralgia                     47                               (47.0)                    1    (1.0)    40    (40.0)    0    
  Diarrhea                       44                               (44.0)                    0             48    (48.0)    2    (2.0)
  Muscle pain                    44                               (44.0)                    1    (1.0)    46    (46.0)    0    
  Nausea                         43                               (43.0)                    1    (1.0)    44    (44.0)    0    
  Stomatitis                     42                               (42.0)                    1    (1.0)    34    (34.0)    0    
  Taste disturbance              42                               (42.0)                    0             67    (67.0)    1    (1.0)
  Edema                          40                               (40.0)                    3    (3.0)    51    (51.0)    4    (4.0)
  Malaise                        40                               (40.0)                    1    (1.0)    44    (44.0)    1    (1.0)
  Loss of appetite               39                               (39.0)                    3    (3.0)    49    (49.0)    0    
  Nasopharyngitis                38                               (38.0)                    0             36    (36.0)    0    
  Fatigue                        33                               (33.0)                    1    (1.0)    31    (31.0)    0    
  Constipation                   25                               (25.0)                    1    (1.0)    30    (30.0)    0    
  Fever                          20                               (20.0)                    0             30    (30.0)    0    

Analysis set: all treated patients.

John Wiley & Sons, Ltd

Dose reductions were required in 65.3% in the *nab*‐paclitaxel arm and 56.6% in the docetaxel arm. The dose‐reduction rates due to neutropenia were 12.0% and 18.0%, and the incidences of grade 4 neutropenia were 35.0% and 89.0% in the *nab*‐paclitaxel and docetaxel arms, respectively. About 6.0% of *nab*‐paclitaxel and 33.0% of docetaxel patients received granulocyte colony‐stimulating factor (G‐CSF). Febrile neutropenia occurred in 1.0% of the *nab*‐paclitaxel arm and 8.0% of the docetaxel arm.

Peripheral sensory neuropathy occurred in 88.0% and 69.0% of the *nab*‐paclitaxel and docetaxel arms, respectively, with the most severe (grade 3) occurring in 22.0% and 5.0%, respectively. The dose reduction rate due to peripheral sensory neuropathy was 33.0% for *nab*‐paclitaxel and 7.0% for docetaxel.

Serious adverse events occurred in 17 patients (17.0%) in the *nab*‐paclitaxel arm and 14 (14.0%) in the docetaxel arm. Most of these serious adverse events were resolved or improved by adequate treatment or study treatment interruption. Adverse events leading to discontinuation occurred in 34.0% of the *nab*‐paclitaxel arm and 37.0% of the docetaxel arm and included peripheral sensory neuropathy (8.0%), edema (4.0%), facial palsy (3.0%), and macular edema (3.0%) in the *nab*‐paclitaxel arm, and edema (10.0%), peripheral sensory neuropathy (7.0%), peripheral edema (6.0%), and interstitial lung disease (4.0%) in the docetaxel arm. No treatment‐related deaths occurred in the present study.

Discussion {#cas13221-sec-0012}
==========

Previous studies have suggested that *sb*‐paclitaxel qw or docetaxel q3w is more effective than *sb*‐paclitaxel q3w for the treatment of breast cancer.[9](#cas13221-bib-0009){ref-type="ref"}, [10](#cas13221-bib-0010){ref-type="ref"} Although *nab*‐paclitaxel qw is already considered as standard therapy in patients with MBC in comparison with *sb*‐paclitaxel q3w, it should also be evaluated in comparison with *sb*‐paclitaxel qw or docetaxel q3w. Given that *nab*‐paclitaxel qw demonstrated dose dependent efficacy in a previous phase II study by Gradishar *et al*.,[19](#cas13221-bib-0019){ref-type="ref"} which showed longer PFS with *nab*‐paclitaxel qw than docetaxel q3w in Western countries, we investigated the efficacy of 150 mg/m^2^ *nab*‐paclitaxel qw. In contrast to the previous study, *nab*‐paclitaxel did not significantly prolong median PFS compared with docetaxel in Japanese patients, and failed to meet the primary endpoint of the study. In calculating our sample size, we estimated the median PFS (11.8 months for *nab*‐paclitaxel and 7.5 months for docetaxel) based on the results of the previous phase II study [19](#cas13221-bib-0019){ref-type="ref"}; however, PFS in the *nab*‐paclitaxel and docetaxel arms were actually 9.8 and 11.2 months, respectively. The patient characteristics in our study differed from those in the previous study; approximately 30% of patients in our study received adjuvant taxane therapy, while patients with prior adjuvant taxane therapy were not enrolled in the previous phase II study. Variation within our study population in terms of prior chemotherapy with taxanes (13.3% *sb*‐paclitaxel and 14.3% docetaxel in *nab*‐paclitaxel arm, and 20.2% *sb*‐paclitaxel and 10.1% docetaxel in docetaxel arm) may also have contributed to the discrepancy between our results and those of the previous study. On the other hand, our stratified analysis demonstrated that the median PFS was longer in patients without prior adjuvant taxane therapy compared with overall patients, similar to the previous phase II study.[19](#cas13221-bib-0019){ref-type="ref"}

The median PFS in the docetaxel arm was longer than originally estimated, which might have been partly because of different dose levels between the two studies. Although the docetaxel dosage in the previous phase II study (100 mg/m^2^) was higher than in the present study (75 mg/m^2^), the median PFS in our docetaxel arm was longer than in reported in the previous study. The results of both the present and previous studies suggest that, although the anti‐tumor efficacy and toxicity of docetaxel are reported to be dose‐dependent in the range of 60--100 mg/m^2^, 75 mg/m^2^ appears to be a better starting dosage in terms of maintaining the relative dose intensity by managing adverse events, demonstrating efficacy in Japanese patients.[24](#cas13221-bib-0024){ref-type="ref"}, [25](#cas13221-bib-0025){ref-type="ref"}, [26](#cas13221-bib-0026){ref-type="ref"} In the present study, patients treated with *nab*‐paclitaxel had a longer median TTF (7.0 months *vs* 5.7 months) and median OS (42.4 months *vs* 34.0 months) compared with docetaxel, though the differences were not significant. Importantly, there was a discrepancy between the PD rates in the *nab*‐paclitaxel arm determined by investigators and those determined by independent radiologist assessment, possibly because investigators analyzed the images taking account of the clinical symptoms of each patient. Assessment of OS is considered to be more objective than PFS. The difference in relative dose intensities between the two treatment arms should also be noted; the median relative dose intensity in the *nab*‐paclitaxel arm was 70.2%, which was lower than that in the docetaxel arm (83.5%), and was also lower than that in the previous phase II study.[27](#cas13221-bib-0027){ref-type="ref"} In our study, the dose reduction rate in the *nab*‐paclitaxel arm was higher than in the docetaxel arm. The relative dose intensity of the standard 80 mg/m^2^ paclitaxel is reported more than 90% [28](#cas13221-bib-0028){ref-type="ref"}. Lower dose intensity might be one of the reasons for PFS not prolonged compared with docetaxel in this study, although treatment with *nab*‐paclitaxel 150 mg/m^2^ qw for multiple cycles was tolerable with dose interruptions or dose reductions, as reported in a phase I study in Japanese patients with MBC.[20](#cas13221-bib-0020){ref-type="ref"}

Subgroup analysis of patients with TNBC in our study showed no significant difference in either PFS or ORR between the two treatment arms, though OS was longer in the *nab*‐paclitaxel arm compared with the docetaxel arm. The GeparSepto study[29](#cas13221-bib-0029){ref-type="ref"} showed that *nab*‐paclitaxel increased the pathological CR rate compared with *sb*‐paclitaxel, as part of sequential taxane--epirubicin/cyclophosphamide neoadjuvant treatment in patients with early breast cancer, implying remarkable efficacy in patients with TNBC. Furthermore, combinations of new immunotherapeutic agents and *nab*‐paclitaxel have recently been tested in patients with TNBC.[30](#cas13221-bib-0030){ref-type="ref"}, [31](#cas13221-bib-0031){ref-type="ref"}, [32](#cas13221-bib-0032){ref-type="ref"} More immunotherapeutic agents are expected to become available, and *nab*‐paclitaxel may thus play a role as a basis for the development of new therapies.

The safety and tolerability profiles of *nab*‐paclitaxel in the present study were similar to those in Gradishar *et al*.\'s phase II study.[19](#cas13221-bib-0019){ref-type="ref"} Docetaxel resulted in a much higher incidence of grade 4 neutropenia than *nab*‐paclitaxel, and more patients in the docetaxel arm required G‐CSF treatment. Febrile neutropenia also occurred more often in the docetaxel arm. Given that febrile neutropenia is risk factor for infection‐related morbidity and mortality, and that frequent G‐CSF use may decrease patient quality of life during treatment, *nab*‐paclitaxel qw may be preferable, especially for elderly or less fit patients. Although the incidence of grade 3 peripheral sensory neuropathy was higher in the *nab*‐paclitaxel arm, this was comparable to previous studies in other countries.[19](#cas13221-bib-0019){ref-type="ref"}

Macular edema has been reported in patients treated with taxanes. In this study, macular edema occurred in nine patients (9.0%), and only in the *nab*‐paclitaxel arm. Careful monitoring of subjective symptoms, such as decreased visual acuity, and appropriate adjustment of the study drug, including dose reduction or interruption, are needed to prevent the symptoms from worsening towards irreversible macular damage.

This was the first randomized study to evaluate the weekly administration of 150 mg/m^2^ *nab*‐paclitaxel in Japanese patients with MBC. Our results suggest that *nab*‐paclitaxel qw shows similar efficacy to docetaxel q3w in Japanese patients. Safety was as expected for *nab*‐paclitaxel and docetaxel; no new profiles were observed, and the frequency of febrile neutropenia was higher in the docetaxel arm. A better understanding of the safety and efficacy profiles of each drug will allow personalized treatments to be proposed based on the individual patient\'s characteristics.
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